Shortages of fuels and chemicals threaten industries from farming to pharmaceuticals https://t.co/wa0k4IgP57 ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of securities of Aquestive Therapeutics, Inc. for the period between June 16, 2025, and January 8, 2026, due to alleged misleading statements regarding the company's New Drug Application for Anaphylm [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Aquestive made false and/or misleading statements and failed to disclose the true state of its New Drug Application for Anaphylm, particularly regarding the human factors involved in the use of its sublingual film [5]. - Investors who purchased Aquestive securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting Phillip Kim, Esq. for more information [3][6]. - A lead plaintiff must move the Court by May 4, 2026, to represent other class members in directing the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Earnings Call InsightsAssertio outlines $110M–$125M 2026 revenue target with Rolvedon at the core while shifting business development approachMar. 16, 2026 6:03 PM ETAssertio Holdings, Inc. (ASRT) StockAI-Generated Earnings Calls InsightsCommentsEarnings Call Insights: Assertio Holdings, Inc. (ASRT) Q4 2025 Management View CEO Mark L. Reisenauer emphasized a shift in Assertio’s growth strategy, stating the company will prioritize driving "significant revenue opportunity in our core asset, Rolvedon," and tha ...

Assertio (NasdaqCM:ASRT) Q4 2025 Earnings call March 16, 2026 04:30 PM ET Company ParticipantsAjay Patel - CFODaniel Santos - SVPMark Reisenauer - CEOPaul Schwichtenberg - President and COORaghuram Selvaraju - Managing DirectorScott Henry - Managing DirectorConference Call ParticipantsNazibur Rahman - VP and Equity Research AnalystThomas Flaten - Senior Research AnalystOperatorLadies and gentlemen, thank you for standing by. My name is Abby, and I will be your conference operator today. At this time, I woul ...

Assertio (NasdaqCM:ASRT) Q4 2025 Earnings call March 16, 2026 04:30 PM ET Speaker4Ladies and gentlemen, thank you for standing by. My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to the Assertio Holdings Fourth Quarter and Full Year 2025 Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during th ...

Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv FILE PHOTO: The logo of Swiss pharmaceutical company Roche is pictured on the company's headquarters in Basel February 4, 2009. REUTERS/Christian Hartmann/File Photo Purchase Licensing Rights, opens new tab BERLIN, March 16 (Reuters) - Swiss drugmaker Roche (ROG.S), opens new tabsaid on Monday it had expanded its artificial intelligence computing capacity with more than 2,100 Nvidia chips to s ...

With the addition of 2,176 NVIDIA Blackwell GPUs, Roche now operates the pharmaceutical industry’s largest announced hybrid-cloud AI factory, totaling more than 3,500 GPUs. The new computational infrastructure supports Roche’s vision of building an AI-accelerated healthcare organisation.NVIDIA AI factories help accelerate discoveries, enable more efficient clinical trials, and unlock data insights at scale, ultimately advancing innovation and improved healthcare outcomes. Basel, 16 March 2026 - Roche (SIX: ...

Rhythm Pharma's obesity drug fails to meet main goal in late-stage trial | Reuters Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv March 16 (Reuters) - Rhythm Pharmaceuticals (RYTM.O), opens new tabsaid on Monday its experimental obesity drug in patients with rare genetic conditions did not meet the main goal of a late-stage trial. Shares of the Boston-based company fell over 7% in extended trading. Purchase Licensing Rights Business Kone i ...

Assertio Reports Fourth Quarter and Full Year 2025 Financial Results Assertio Reports Fourth Quarter and Full Year 2025 Financial Results Share Delivers FY2025 Net Product Sales and Adjusted EBITDA Above Guidance Expects Net Product Sales between $110M-$125M and Adjusted EBITDA between $28M-$40M in FY2026 LAKE FOREST, Ill--(BUSINESS WIRE)--Assertio Holdings, Inc. ("Assertio†or the "Company†) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated product ...

NEWARK, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the second quarter fiscal year 2026 ended January 31, 2026. “We remain pleased with the progress of our pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, which the Data Monitoring Committee (DMC) recommended continuing after their review of prespecified safety and efficacy data at 48 weeks. We believe that Trappsol® Cyclo ...